We are live on ! Find out more
ABBV icon

AbbVie

1,692 hedge funds and large institutions have $68.3B invested in AbbVie in 2016 Q4 according to their latest regulatory filings, with 147 funds opening new positions, 648 increasing their positions, 669 reducing their positions, and 86 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 147 | Existing positions closed: 86

5% more funds holding in top 10

Funds holding in top 10: 8185 (+4)

2% more funds holding

Funds holding: 1,6541,692 (+38)

1% more call options, than puts

Call options by funds: $1.06B | Put options by funds: $1.04B

2% less capital invested

Capital invested by funds: $69.4B → $68.3B (-$1.08B)

3% less repeat investments, than reductions

Existing positions increased: 648 | Existing positions reduced: 669

1.09% less ownership

Funds ownership: 68.28%67.19% (-1.1%)

Holders
1,692
Holders Change
+38
Holders Change %
+2.3%
% of All Funds
42.29%
Holding in Top 10
85
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+4.94%
% of All Funds
2.12%
New
147
Increased
648
Reduced
669
Closed
86
Calls
$1.06B
Puts
$1.04B
Net Calls
+$12.1M
Net Calls Change
+$127M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
26
Prudential plc
United Kingdom
$439M +$48M +786,487 +13%
Deutsche Bank
27
Deutsche Bank
Germany
$427M -$124M -2,027,823 -23%
EIP
28
Epoch Investment Partners
New York
$423M -$5.05M -82,718 -1%
Invesco
29
Invesco
Georgia
$420M -$46.9M -767,876 -10%
LSV Asset Management
30
LSV Asset Management
Illinois
$405M +$49.7M +814,130 +14%
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$395M -$16.4M -268,546 -4%
Fidelity Investments
32
Fidelity Investments
Massachusetts
$385M -$313M -5,123,067 -45%
HCM
33
Highfields Capital Management
Massachusetts
$372M -$123M -2,014,581 -25%
OAG
34
Orbis Allan Gray
Bermuda
$343M +$35.4M +579,378 +12%
UBS AM
35
UBS AM
Illinois
$339M +$18.1M +296,622 +6%
Capital World Investors
36
Capital World Investors
California
$330M -$91.6M -1,500,000 -22%
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$316M -$68.2M -1,116,673 -18%
Charles Schwab
38
Charles Schwab
California
$313M +$6.45M +105,607 +2%
Franklin Resources
39
Franklin Resources
California
$312M -$24.8M -406,387 -8%
PNC Financial Services Group
40
PNC Financial Services Group
Pennsylvania
$296M -$4.04M -66,169 -1%
Swiss National Bank
41
Swiss National Bank
Switzerland
$284M +$3.06M +50,100 +1%
Sumitomo Mitsui Trust Group
42
Sumitomo Mitsui Trust Group
Japan
$283M -$11.2M -183,442 -4%
Aristotle Capital Management
43
Aristotle Capital Management
California
$274M +$10.8M +176,116 +4%
CS
44
Credit Suisse
Switzerland
$265M -$11.9M -194,562 -4%
Fayez Sarofim & Co
45
Fayez Sarofim & Co
Texas
$263M -$11M -180,093 -4%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$260M -$5.79M -94,800 -2%
BIM
47
BlackRock Investment Management
Delaware
$254M +$10.9M +178,702 +5%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$250M -$3.49M -57,200 -1%
BlackRock
49
BlackRock
New York
$249M -$12.9M -210,973 -5%
RJA
50
Raymond James & Associates
Florida
$243M +$54.5M +893,454 +30%

ABBV Hedge Fund Activity: Q4 2016 in Review

1,692 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2016, worth a combined $68.3B — down 1.6% from $69.4B a quarter earlier.

Buyers outnumbered sellers: 147 funds opened new ABBV positions and 86 closed out — a net gain of 61 holders — while 648 added to existing stakes and 669 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $836M. The largest seller was Baker Bros. Advisors, cutting an estimated $773M.

  • 1,692 institutional investors held AbbVie (ABBV) as of Q4 2016, up from 1,654 in Q3 2016.
  • Funds reported $68.3B of AbbVie stock for Q4 2016, down 1.6% quarter-over-quarter.
  • 147 funds opened new AbbVie positions in Q4 2016 and 86 closed out, a net change of +61 holders.
  • The largest AbbVie buyer in Q4 2016 was Capital Research Global Investors, an estimated $836M added.
  • The largest AbbVie seller in Q4 2016 was Baker Bros. Advisors, an estimated $773M sold.

Based on aggregated 13F filings for Q4 2016.